Sign in
Taking peoplePhase 2/3

Dapagliflozin and empagliflozin added to usual care for adults with nephrotic syndrome

Tests dapagliflozin or empagliflozin alongside usual care in adults with primary nephrotic syndrome.

Key facts

Who runs it
Mansoura University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Status
Recruiting
Phase
Phase 2/3
People taking part
75 people, planned
Started
15 Nov 2025
Planned end
6 Sept 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dapagliflozin
  • Empagliflozin
  • Standard Therapy
Record updated
9 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary nephrotic syndrome, a kidney disease that causes a lot of protein loss in the urine. It tests dapagliflozin or empagliflozin added to standard therapy.

Age
18 years and older
Sex
All sexes
Disease stage
Primary nephrotic syndrome confirmed by a kidney biopsy (for example idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis). Kidney function (eGFR) must be ≥25 mL/min/1.73m².
Earlier treatment
People must be on a stable dose of immunosuppressive therapy and kidney-protecting medicines for ≥4 weeks before joining.
Biomarker or test result
eGFR ≥25 mL/min/1.73m² by the CKD-EPI formula.

Main reasons for not taking part

  • Nephrotic syndrome caused by another disease, such as diabetes mellitus, lupus nephritis or amyloidosis
  • Liver tests (ALT or AST) above 3 times the upper limit of normal
  • Blood in the urine from the kidney filters (more than 10 red cells per high power field, more than 3 times in the last 2 weeks)
  • Severe allergy to, or reasons not to take, dapagliflozin or empagliflozin
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adult patients (≥18 years). Biopsy-confirmed primary nephrotic syndrome (e.g., idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis)
  • Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m² using CKD-EPI formula
  • On stable dose of immunosuppressive therapy and renoprotective agents for ≥4 weeks prior to randomization
  • Able to signed informed consent

Who cannot take part

  • Diagnosis of secondary nephrotic syndrome as : diabetes mellitus, lupus nephritis, and amyloidosis
  • History of severe hypersensitivity or contraindications to dapagliflozin or empagliflozine
  • Impaired liver functions (ALT or AST values exceeding 3 folds upper limit of normal (ULN) at the screening visit)
  • Glomerular hematuria (red blood cells more than ten cells per high power field (HPF) after routine urinalysis for more than three times in the last 2 weeks)
  • Pregnancy or breastfeeding

This trial is currently available in Egypt.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone.

Read full original descriptionShow less

The primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, serum creatinine) and monitoring safety outcomes.

Participants will continue their baseline standard care and will be followed for 6 months with regular clinical evaluations, laboratory tests, and adverse event monitoring.

The 3 groups in the trial

  • Dapagliflozin + Standard of CareTreatment being tested

    Treatment: Dapagliflozin and Standard Therapy

  • Empagliflozin + Standard of CareTreatment being tested

    Treatment: Empagliflozin and Standard Therapy

  • Standard of Care OnlyExisting treatment, for comparison

    Standard treatment protocol(institutional standared) for 6 months without any additional SGLT2 inhibitor.

    Treatment: Standard Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled Trial
Plain-language title
Dapagliflozin and empagliflozin added to usual care for adults with nephrotic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
9 June 2026